BNF January 2023 Update

This update contains 4 significant changes, 3 dose changes, 4 new monographs and 2 new preparations.

Significant Changes:

• Contraceptives, interactions: updated guidance.
• Depression: updated guidance on management.
• Hypertension: updated guidance for the management of patients with type 1 diabetes.
• Ozanimod (Zeposia®): new indication for ulcerative colitis.

Dose Changes:

• Abilify Maintena® (aripiprazole) [addition of alternative initiation dosing].
• Benlysta® (belimumab) [addition of subcutaneous dosing].
• Cimzia® (certolizumab pegol) [update to dosing for ankylosing spondylitis].

New Monographs:

• Drovelis® [drospirenone with estetrol].
• Giapreza® [angiotensin II].
• Hepcludex® [bulevirtide].
• Welireg® [belzutifan].

New Preparations:

• Efmody® [hydrocortisone]
• Okedi® [risperidone].